Walleye Capital
RYTM icon

Walleye Capital’s Rhythm Pharmaceuticals RYTM Stock Holding History

Walleye Capital’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-50,181
Closed -$5.07M – 5042
2025
Q3 		$5.07M Buy
+50,181
New +$4.66M 0.02% 920
2025
Q2 		– Sell
-35,828
Closed -$1.9M – 4970
2025
Q1 		$1.9M Sell
35,828
-108,514
-75% -$6.02M 0.01% 1459
2024
Q4 		$8.08M Buy
+144,342
New +$7.97M 0.02% 773
2023
Q3 		– Sell
-395,541
Closed -$6.52M – 5270
2023
Q2 		$6.52M Buy
395,541
+257,772
+187% +$4.65M 0.02% 591
2023
Q1 		$2.46M Buy
+137,769
New +$3.46M 0.04% 608
2022
Q4 		– Sell
-191,373
Closed -$4.69M – 3573
2022
Q3 		$4.69M Buy
+191,373
New +$3.56M 0.09% 246
2021
Q4 		– Sell
-49,845
Closed -$651 – 2286
2021
Q3 		$651 Buy
+49,845
New +$761K 0.02% 670

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Walleye Capital's RYTM Position: Q4 2025 in Review

Walleye Capital sold out of Rhythm Pharmaceuticals (RYTM) in Q4 2025, closing a stake of 50,181 shares — an estimated $5.07M sold.

Walleye Capital first reported a position in RYTM in Q3 2021 and held it in 7 quarters. The position peaked at $8.08M in Q4 2024. 279 funds tracked by Wall St. Rank hold RYTM as of Q4 2025.

  • Walleye Capital reported no remaining Rhythm Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Walleye Capital sold 50,181 Rhythm Pharmaceuticals shares in Q4 2025, an estimated $5.07M.
  • Walleye Capital first reported a position in Rhythm Pharmaceuticals in Q3 2021 and held it in 7 quarters.
  • Walleye Capital's Rhythm Pharmaceuticals position peaked at $8.08M in Q4 2024.
  • 279 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q4 2025.

Based on Walleye Capital's 13F filing for Q4 2025, filed 13 Feb 2026.